104 Pluripotent Fetal Stem Cells for Treatment of the Vascular Factor of Erectile Dysfunction

Miroshnykov, Y.O.; Klunnyk, Mariya; Sych, Nataliia; Sinelnyk, Andriy; Sorochynska, Khrystyna; Kerus, S.; Chen, J.

doi:10.1016/j.jsxm.2016.11.057

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LIST alone or stem cells alone may contribute independently to positive outcomes for ED adding complexity to the data interpretation on this combined study. Review of world human literature for the use of stem cells alone for ED shows limited efficacy with results generally ranging in the 33-67% range [15][16][17][18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…There have been numerous animal studies in the literature since 2004 dealing with the use of various progenitor cells deployed in different ways to improve erectile tissue histology or function, with the vast majority demonstrating positive results [11][12][13]. The number of human publications on the effects of cellular therapy on ED is extremely low considering that ED is prevalent in more than 30 million men in the United States alone [14][15][16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autologous Stromal Vascular Fraction Containing Stem Cells Combined with Low Intensity Shock Wave for the Treatment of Human Erectile Dysfunction

Lander¹,

Berman²

2018

J Stem Cell Res Ther

View full text Add to dashboard Cite

Objective: This study seeks to determine whether the addition of autologous Adipose-Derived Stem Cells (ADSCs) may safely synergize with the clinical effects of Low-Intensity Shock Wave Therapy (LIST) to improve Erectile Dysfunction (ED) in a small series of men. Methods: Under IRB protocols, 52 patients with multifactorial ED were treated with LIST immediately followed by a single intracavernosal injection of lipoaspirate derived autologous Stromal Vascular Fraction (SVF). Human SVF derived using our protocols has been shown to contain Mesenchymal Stem Cells (MSCs) and Hematopoietic Stem Cells (HSCs). Subjective outcomes testing with the International Index of Erectile Function (IIEF) Score and Erectile Hardness Score (EHS) were administered to the patients at baseline and every 3 months for 2 years. All patients were queried for adverse reactions and all outcomes were self-reported. Results: Excellent safety was seen and none of the patients experienced any adverse reactions related to LIST or harvesting and deployment of SVF. A retrospective review of efficacy indicated that 37 out of 52 patients (71%) responded positively to the question of whether they experienced "overall improvement" after their treatment. Mean IIEF reference questionnaire scores and Mean Erectile Hardness Grading Score (EHS) were also reported by patients. Mean IIEF scores went from 10.21 baseline to 18.40 at 6 months (p=0.0008). Mean EHS scores improved from 1.34 baseline to 2.17 at 6 months (p=0.012). Conclusion: Intracavernosal deployment of autologous SVF combined with low-intensity acoustic shock wave therapy to the penis appears to be safe and may offer some benefits to a cross-section of patients who suffer from ED. Larger trials are indicated to identify which types of stem cells are optimal, which subsets of ED patients appear to benefit the most, and which types of shock wave protocols yield the best results.

show abstract

Section: Discussionmentioning

confidence: 99%